Prestige BioPharma secures EMAs positive opinion for Herceptin biosimilar - KBR
334970 Stock | KRW 5,260 60.00 1.13% |
About 61% of Prestige Biologics' investor base is looking to short. The analysis of current outlook of investing in Prestige Biologics Co suggests that many traders are alarmed regarding Prestige Biologics' prospects. The current market sentiment, together with Prestige Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use Prestige Biologics stock news signals to limit their universe of possible portfolio assets.
Prestige |
Prestige BioPharma secures EMAs positive opinion for Herceptin biosimilar KBR
Read at news.google.com
Prestige Biologics Fundamental Analysis
We analyze Prestige Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prestige Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prestige Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Prestige Biologics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Prestige Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Prestige Biologics stock to make a market-neutral strategy. Peer analysis of Prestige Biologics could also be used in its relative valuation, which is a method of valuing Prestige Biologics by comparing valuation metrics with similar companies.
Peers
Prestige Biologics Related Equities
041510 | SM Entertainment | 1.69 | ||||
094360 | ChipsMedia | 1.60 | ||||
089600 | Nasmedia | 1.25 | ||||
263720 | DC Media | 1.23 | ||||
033230 | Insung Information | 0.36 |
Complementary Tools for Prestige Stock analysis
When running Prestige Biologics' price analysis, check to measure Prestige Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prestige Biologics is operating at the current time. Most of Prestige Biologics' value examination focuses on studying past and present price action to predict the probability of Prestige Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prestige Biologics' price. Additionally, you may evaluate how the addition of Prestige Biologics to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |